Form 4: Intra-Cellular Therapies Director, Robert L. Van Nostrand, Reports Stock Option and Restricted Stock Unit Grant

Robert L. Van Nostrand, a director at Intra-Cellular Therapies, Inc., reports the acquisition of stock options and restricted stock units.

Summary

• On June 14, 2024, Robert L. Van Nostrand, a director of Intra-Cellular Therapies, Inc., reported the acquisition of 4,322 stock options and 2,951 restricted stock units (RSUs).
• The stock options have an exercise price of $67.77 and expire on June 13, 2034.
• The RSUs vest on June 14, 2025, and each unit represents a contingent right to receive one share of common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices, aligning director interests with shareholders.

Positives

• The grant of stock options and RSUs to a director aligns their interests with those of the shareholders.
• The vesting schedule of the RSUs (June 14, 2025) encourages long-term commitment from the director.

Industry Context

Stock options and restricted stock units are common forms of executive compensation in the biotechnology industry, aligning management's interests with shareholder value.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are standard practice in the pharmaceutical and biotechnology industries.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize similar equity-based compensation to incentivize their executives and directors.
• The specific amounts and vesting schedules vary based on company size, performance, and individual roles.

Stakeholder Impact

• The grant of stock options and RSUs can positively impact shareholders by aligning the director's interests with the company's long-term success.
• Employees may view this as a positive sign of the company's commitment to its leadership.

Key Dates